Ophthalmic Drugs Market to Grow with an Impressive CAGR During the Forecast Period
Rising concerns
for fertility is driving the growth in Global Ophthalmic Drugs Market in the
forecast period, 2022-2026.
According to TechSci Research report, “Global Ophthalmic
Drugs Market
By Drug Class (Anti-Inflammatory Drugs, Anti-Infection Drugs, Anti-Allergic
Drugs, Anti-Glaucoma Drugs, Others) By Indication (Dry Eye, Eye Allergy,
Glaucoma, Eye Infection, Others) By Product Type (OTC Drugs v/s Prescription
Drugs) By Dosage Form (Gels, Ointments, Eye Solutions, Eye Drops, Tablets
&Capsules) By Route of Administration (Topical, Ocular, Systemic) By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) By
Region, Competition Forecast & Opportunities, 2026”, the global ophthalmic drugs market may potentially project an
impressive growth in the forecast period, 2022-2026, with an impressive CAGR on
the account of rising number of patients suffering from eye diseases and vision
related disorders. Moreover, the rising number of geriatric population and
their tendency to suffer from the eye diseases is further aiding the growth of
the market in the next five years. Furthermore, increasing instances of
cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus
retinitis, and age-related macular degeneration are also supporting the market
growth.
Browse over XX
market data Figures spread through 110 Pages
and an in-depth TOC on "Global Ophthalmic Drugs Market"
https://www.techsciresearch.com/report/ophthalmic-drugs-market/7633.html
The global ophthalmic drugs market is segmented by
drug class, indication, product type, dosage form, route of administration,
distribution channel, competitional landscape, and regional distribution. Based
on indication, the market is further bifurcated into dry eye, eye allergy,
glaucoma, eye infection, and others. Glaucoma is expected to register largest
shares of the market and is anticipated to assert its dominance over the market
segment on the account of increasing instances of the disease as well as the
large population that is being affected. Moreover, the lifestyle choices and
unhealthy food habits has aided to the ever-increasing patient count of
diabetes and glaucoma therewith. The factors are intensely responsible for the
growth of the market segment.
Based on product type, the market is further
divided between, OTC drugs and prescription drugs. Prescription drugs have
dominated the historical years and is anticipated to dominate the market in the
next five years, on the account of improved safety and efficacy profiles of
these drugs. OTC drugs are anticipated to register fastest growing CAGR on the
backbone of advantages like easy accessibility to the patient. OTC drug market
is largest in the Asia Pacific region and the demand from the region is aiding
to the growth of the global market. Market players with the prescription drugs
may suffer a mild restraint due to availability of the OTC drugs. For example, the U.S. FDA has approved Alcon’s Pataday (olopatadine
hydrochloride ophthalmic solution 0.7%) for OTC to treat eye allergy. Formerly,
it was prescribed under the name of Pazeo. The development of this OTC
ophthalmic solution is expected to increase the number of patients for
Pataday's product portfolio.
Holding the major shares of the global ophthalmic
drugs market are AbbVie Inc. (Allergan), Bausch Health Companies Inc., Johnson
& Johnson, F. Hoffmann-La Roche Ltd., Hoya Corporation, Novartis AG, Pfizer
Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Alcon
Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.,
Cipla Ltd., Merck & Co., Inc., Coherus Biosciences, Inc., among others.
Market players are actively involved in the research and technological
development in the pharmaceuticals and drugs department. The advanced
technology has made it possible for the healthcare industry to provide
excellent healthcare services through Ophthalmic Drugs. Further advancement
would aid the market value and brand establishment in the future five years. New market players may focus on the research
and development to provide options that satisfies the consumer demand as well
as benefits the market players in building their brand value. Other competitive
strategies include mergers & acquisitions and new product developments.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7633
Customers can also request for
10% free customization on this report.
“Asia Pacific is
anticipated to be the most volatile and most promising market in the future
five years. Anti-glaucoma and dry eye drugs are rapidly increasing in the
region. Large economies like India and China are further aiding the growth of
the market in the upcoming five years. Furthermore, rapidly increasing
population of middle-class households along with the technological advancements
in the medical infrastructures and increasing financial aids for the medical
insurances is supporting the growth of the global ophthalmic drug market,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
Global management consulting firm.
“Global Ophthalmic Drugs
Market By Drug Class (Anti-Inflammatory Drugs, Anti-Infection Drugs,
Anti-Allergic Drugs, Anti-Glaucoma Drugs, Others) By Indication (Dry Eye, Eye
Allergy, Glaucoma, Eye Infection, Others) By Product Type (OTC Drugs v/s
Prescription Drugs) By Dosage Form (Gels, Ointments, Eye Solutions, Eye Drops,
Tablets &Capsules) By Route of Administration (Topical, Ocular, Systemic) By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) By
Region, Competition Forecast & Opportunities, 2026”, has evaluated the
future growth potential of global ophthalmic drugs and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global ophthalmic drugs market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/